Azidothymidine in the Treatment of AIDS

To the Editor: Richman et al., in reviewing the experience of the AZT Collaborative Working Group on the toxicity of azidothymidine (zidovudine [Retrovir], or AZT) in the July 23 issue,* reported that 45 percent of patients receiving AZT had some hematologic toxic effects. They also reported that most patients receiving AZT had at least one clinical symptom, such as headache, asthenia, diarrhea, abdominal pain, or fever, but they did not report that any patients had neurologic symptoms. We have recently seen a 43-year-old male patient, positive for antibodies to the human immunodeficiency virus (HIV), who had grand mal epileptic seizures . . . No extract is available for articles shorter than 400 words.